Peptipedia
Anti-AgingNot FDA ApprovedClinical Trials

DSIP

Also known as Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide

A peptide studied for its ability to promote deep sleep and modulate stress hormones.

Investigational - Mixed research results
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

100-250 mcg before bed

Frequency

Once daily, 30 minutes before sleep

Duration

2-4 weeks typical

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 100-250 mcg before bed via Subcutaneous, intramuscular, or intranasal, Once daily, 30 minutes before sleep. Dose range: 50-300 mcg per dose. Duration: 2-4 weeks typical.

Timing & Administration

Administer via Subcutaneous, intramuscular, or intranasal. Frequency: Once daily, 30 minutes before sleep.

Mechanism of Action

Operates on serotonin, dopamine, and GABA systems. Modulates cortisol secretion and promotes delta wave (deep sleep) patterns without suppressing REM sleep.

Research Summary

Evidence level: clinical trials. Clinical status: Investigational - Mixed research results.

Side Effects & Safety

Important Warnings

  • Caution with MCAS or histamine sensitivity
  • Limited clinical data.
Fatigue upon waking (dose-dependent)
injection site reactions
headache
nausea
potential histamine release
immunogenicity risk

References

No references available.

Related Peptides

Browse all →
HumaninAnti-Aging

A mitochondria-derived peptide discovered for its neuroprotective effects against Alzheimer's-related toxicity.

View profile
NAD+ PrecursorsAnti-Aging

While not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.

View profile
SS-31Anti-Aging

A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome in September 2025.

View profile